CMS Forward-Backward MSGC milestone

The CMS MF1 milestone was set in order to evaluate system aspects of the CMS forward-backward MSGC tracker, to check the design and feasibility of mass production and to set up assembly and test procedures. We describe the construction and the experience gained with the operation of a system of 38 MSGC detectors assembled in six multi-substrate detector modules corresponding to the geometry of the forward-backward MSGC tracker in CMS. These modules were equipped with MSGCs mounted side by side, forming a continuous detector surface of about 0.2 m2. Different designs were tried for these modules. The problems encountered are presented with the proposed solutions. Operation conditions for the 38 MSGCs are reported from an exposure to a muon beam at the CERN SPS. Gain uniformity along the wedge-shaped strip pattern and across the detector modules are shown together with the detection efficiency, the spatial resolution, alignment and edge studies

CMS physics technical design report : Addendum on high density QCD with heavy ions

Peer reviewe

Treatment of common ocular allergic disorders; a comparison of lodoxamide and NAAGA

BACKGROUND/AIMS—Lodoxamide tromethamine and N-acetyl-aspartyl glutamic acid (NAAGA) are mast cell stabilisers, both of which have been shown to be effective in the treatment of allergic conjunctivitis. The aim of this study was to compare the two compounds in patients with common ocular allergic disorders.
METHODS—73 patients participated in a double masked, randomised multicentre study. Diagnoses were chronic allergic conjunctivitis, vernal conjunctivitis, seasonal and atopic conjunctivitis. 36( )patients were treated with lodoxamide 0.1% and 37 with NAAGA 4.9%, the drops being instilled four times daily for up to 56( )days.
RESULTS—The overall opinion of the physicians and the patients was in favour of lodoxamide at day 10 of the study. At this time, 86% of lodoxamide treated and 49% of NAAGA treated patients considered they had improved. The patients' opinion favoured lodoxamide at day 28 and both physicians' and patients' evaluations were in favour of lodoxamide at day 42. Evaluation of signs and symptoms indicated superiority of lodoxamide at days 42 and 56. Both treatments were well tolerated.
CONCLUSION—While both lodoxamide and NAAGA treatments are associated with clinical improvements in patients with allergic conjunctivitis, lodoxamide may have an earlier onset of action.

 Keywords: allergic conjunctivitis; lodoxamide; NAAGA; topical therap

Treatment of common ocular allergic disorders; a comparison of lodoxamide and NAAGA.

--

KAP1 is an antiparallel dimer with a functional asymmetry

KAP1 (KRAB domain-associated protein 1) plays a fundamental role in regulating gene expression in mammalian cells by recruiting different transcription factors and altering the chromatin state. In doing so, KAP1 acts both as a platform for macromolecular interactions and as an E3 small ubiquitin modifier ligase. This work sheds light on the overall organization of the full-length protein combining solution scattering data, integrative modeling, and single-molecule experiments. We show that KAP1 is an elongated antiparallel dimer with an asymmetry at the C-terminal domains. This conformation is consistent with the finding that the Really Interesting New Gene (RING) domain contributes to KAP1 auto-SUMOylation. Importantly, this intrinsic asymmetry has key functional implications for the KAP1 network of interactions, as the heterochromatin protein 1 (HP1) occupies only one of the two putative HP1 binding sites on the KAP1 dimer, resulting in an unexpected stoichiometry, even in the context of chromatin fibers